Drug development for carcinoma of the prostate.
D000477:Alkylating Agents / Q000627:therapeutic use; D000726:Androgen Antagonists; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000627:therapeutic use*; D004967:Estrogens / Q000627:therapeutic use; D005485:Flutamide / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008535:Megestrol / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013256:Steroids / Q000031:analogs & derivatives
D000477:Alkylating Agents; D000726:Androgen Antagonists; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D004967:Estrogens; D013256:Steroids; D005485:Flutamide; D008535:Megestrol